%0 Journal Article
%T MRI-based machine learning radiomics for prediction of HER2 expression status in breast invasive ductal carcinoma.
%A Luo HJ
%A Ren JL
%A Mei Guo L
%A Liang Niu J
%A Song XL
%J Eur J Radiol Open
%V 13
%N 0
%D 2024 Dec
%M 39149534
暂无%R 10.1016/j.ejro.2024.100592
%X <B>UNASSIGNED: </B>Human epidermal growth factor receptor 2 (HER2) is a tumor biomarker with significant prognostic and therapeutic implications for invasive ductal breast carcinoma (IDC).<BR><B>UNASSIGNED: </B>This study aimed to explore the effectiveness of a multisequence magnetic resonance imaging (MRI)-based machine learning radiomics model in classifying the expression status of HER2, including HER2-positive, HER2-low, and HER2 completely negative (HER2-zero), among patients with IDC.<BR><B>UNASSIGNED: </B>A total of 402 female patients with IDC confirmed through surgical pathology were enrolled and subsequently divided into a training group (n = 250, center I) and a validation group (n = 152, center II). Radiomics features were extracted from the preoperative MRI. A simulated annealing algorithm was used for key feature selection. Two classification tasks were performed: task 1, the classification of HER2-positive vs. HER2-negative (HER2-low and HER2-zero), and task 2, the classification of HER2-low vs. HER2-zero. Logistic regression, random forest (RF), and support vector machine were conducted to establish radiomics models. The performance of the models was evaluated using the area under the curve (AUC) of the operating characteristics (ROC).<BR><B>UNASSIGNED: </B>In total, 4506 radiomics features were extracted from multisequence MRI. A radiomics model for prediction of expression state of HER2 was successfully developed. Among the three classification algorithms, RF achieved the highest performance in classifying HER2-positive from HER2-negative and HER2-low from HER2-zero, with AUC values of 0.777 and 0.731, respectively.<BR><B>UNASSIGNED: </B>Machine learning-based MRI radiomics may aid in the non-invasive prediction of the different expression status of HER2 in IDC.